

VPA10803/002/001

Trigoderm Gel 0.5 % w/w Fusidic acid, 0.1 % w/w Betamethasone

Variation	Summary	Date
Vet - G.I.18	VRA-S - Vet - G.I.18 - - Vet - G.I.18 - One-off alignment of the product information with version 9.0* of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products authorised in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	31/07/26
Vet - F.II.d.2 b)	VRA-R - Vet - F.II.d.2 b) - - Vet - F.II.d.2 b) - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	21/07/26
Vet - B44 a)	VNRA - Vet - B44 a) - - Vet - B44 a) - Submission of a Ph. Eur. CEP for:— active substance;— starting material, reagent or intermediate used in the manufacturing process of the active substance;— excipient - Updated certificate	14/04/26
Vet - F.II.f.1 z)	VRA-R - Vet - F.II.f.1 z) - - Vet - F.II.f.1 z) - Change in the shelf-life or storage conditions of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance	05/03/26
Vet - B39	VNRA - Vet - B39 - Change in any part of the primary packaging material not in contact with the finished product formulation - B39 Changes to the quality part of the dossier: Change in any part of the primary packaging material not in contact with the finished product formulation (such as change of colour due to different plastic used for flip-off caps, colour code rings on ampoules or change of needle shield)	24/04/25
Vet - B3 e)	VNRA - Vet - B3 e) - e) Deletion of a test procedure - B3 e) Changes to the quality part of the dossier: Deletion of a test procedure — for the active substance or a starting material, reagent or intermediate of the active substance; —for the immediate packaging of the active substance; — for an excipient or the finished product; —for the immediate packaging of the finished product	02/12/24
Vet - G.I.15 z)	VRA-R - Vet - G.I.15 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - G.I.15 z) Safety, Efficacy, Pharmacovigilance changes - Changes to the labelling or the package leaflet which are not connected with the summary of product characteristics - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	18/09/24
Vet - F.II.d.2 z)	VRA-R - Vet - F.II.d.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.d.2 z) Quality Changes - Finished Product -Control of finished product - Change in	16/04/24

	test procedure for the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	
Vet - F.III.1 a) z.	VRA-S - Vet - F.III.1 a) z. - a) European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph. z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.III.1 a) z. Quality Changes - CEP/TSE/MONOGRAPHS -Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: -For an active substance -For a starting material/reagent/intermediate used in the manufacturing process of the active substance -For an excipient European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	05/10/23
Vet - G.I.15 z)	VRA-R - Vet - G.I.15 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - G.I.15 z) Safety, Efficacy, Pharmacovigilance changes - Changes to the labelling or the package leaflet which are not connected with the summary of product characteristics - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	12/12/22
Vet - F.II.b.3 h)	VRA-S - Vet - F.II.b.3 h) - h) Change in the holding time of an intermediate or bulk product (if applicable) - F.II.b.3 h) Quality Changes - Finished Product -Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Change in the holding time of an intermediate or bulk product (if applicable)	18/10/22
Vet - C10 a)	VNRA - Vet - C10 a) - a) Administrative information concerning the holder's representative - C10 a) Changes to the safety, efficacy and pharmacovigilance part of the dossier: Changes to the labelling or the package leaflet which shall not be connected with the SPC: — administrative information concerning the holder's representative	19/07/22
Vet - B3 a)	VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier) - B3 a) Changes to the quality part of the dossier: Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control	19/07/22

	takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier)	
Vet - B30 c)	VNRA - Vet - B30 c) - c) Addition of a new specification parameter to the specification with its corresponding test method - B30 c) Changes to the quality part of the dossier: Change in the specification parameters or limits of the finished product: —addition of a new specification parameter to the specification with its corresponding test method	13/07/22
Vet - B12 a)	VNRA - Vet - B12 a) - a) Minor changes to an approved test procedure (active, finished product, packaging, measuring device) - B12 a) Changes to the quality part of the dossier: Minor changes — to an approved test procedure — for active substance; — for the finished product; —for the immediate packaging of the active substance or the finished product; — of a measuring or administration device	13/07/22
Vet - B44(Do not use)	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	23/05/22
Vet - B3 a)	VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier) - B3 a) Changes to the quality part of the dossier: Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier)	13/05/22